Open innovation: Chances and challenges for the pharmaceutical industry

Future Medicinal Chemistry

Volumn 1, Issue 7, 2009, Pages 1197-1200

  Niedergassel, Benjamin ^a   Leker, Jens ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTECHNOLOGY; DRUG INDUSTRY; DRUG RESEARCH; EDITORIAL; KNOWLEDGE; ORGANIZATION; PRIORITY JOURNAL;

ACADEMIES AND INSTITUTES; DRUG INDUSTRY; RESEARCH;

EID: 77953431723     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.09.107     Document Type: Editorial

References (25)

1. US National Science Foundation. Science and Engineering Indicators. NSF, Arlington, VA, USA (2008).
2. Gassmann O, Reepmeyer G, von Zedtwitz M. Leading Pharmaceutical Innovation - Trends and Drivers for Growth in the Pharmaceutical Industry. Springer-Verlag, Berlin, Germany (2004).
3. DiMasi JA, Grabowski HG. The cost of biopharmaceutical R&D. Is biotech different? Managerial Decision Economics 28, 469-479 (2007).
4. Horrobin DF. Innovation in the pharmaceutical industry. J. Royal Soc. Med. 93, 341-345 (2000).
5. Gassmann O, Reepmeyer G. Organizing pharmaceutical innovation. From science-based knowledge creators to drug-oriented knowledge brokers. Creativity Innovation Management 14, 233-245 (2005).
6. Niedergassel B, Curran C-S, Leßing M, Leker J. What drives partners in industry-academia cooperation? Int. J. Tech. Intelligence Planning 3, 331-342 (2007).
7. Chesbrough HW. Open innovation. A new paradigm for understanding industrial innovation. In: Open Innovation: Researching a New Paradigm. Chesbrough HW, Vanhaverbeke W, West J (Eds). Oxford University Press, Oxford, UK, 1-12 (2006).
8. Chesbrough HW. The era of open innovation. MIT Sloan Manag. Rev. 35-41 (2003).
9. OECD. Open Innovation in Global Networks. OECD Publications, Paris, France (2008).
10. Blumenthal D, Causino N, Campbell E, Louis KS. Relationships between academic institutions and industry in the life sciences - an industry survey. N. Engl. J. Med. 334, 368-373 (1996).
11. Anonymous. The potential of partnering. Nat. Rev. Drug Discov. 7, 187 (2008).
12. Mudhar P. Pharma-biotech alliances. Pharmaceutical Technology Europe 18, 18-22 (2006).
13. Butkus B. Big Pharma's academic courtship continues with Pfizer-UCSF, Glaxo-IDI research pacts. Biotech Transfer Week. 11 June 2008.
14. Niedergassel B, Leker J. Tacit and explicit knowledge sharing in collaborative R&D projects. Presented at: 18th International Conference on Management of Technology. Orlando, FL, USA, 5-9 April 2009.
15. Cyert RM, Goodman PS. Creating effective university-industry alliances. An organizational learning perspective. Organizational Dynamics 25, 45-57 (1997).
16. Lopez-Martinez RE, Medellin E, Scanlon AP, Solleiro JL. Motivations and obstacles to university industry cooperation (UIC) - a Mexican case. R&D Management 24, 17-31 (1994).
17. Fisher R. A marriage of opposites. New Scientist 190, 58-61 (2006).
18. Herzog P. Open and Closed Innovation - Different Cultures for Different Strategies. Wiesbaden, Gabler, Germany (2008).
19. Herzog P, Leker J. Open vs. closed innovation units. Different cultures for different strategies. Presented at: International Society for Professional Innovation Management Conference. Warsaw, Poland, 17-20 June 2007.
20. Herzog P, Leker J. Open vs. closed innovation strategies, also different innovation cultures? Presented at: R&D Management Conference. Bremen, Germany, 4-6 July 2007.
21. Herzog P, Leker J. Open and closed innovation - different innovation cultures for different strategies. Int. J. Innovation Tech. Management (2009) (In press).
22. Niedergassel B, Leker J. Collaborative R&D Projects. Differences between University- University and University-Industry Partnerships. Presented at: International Society for Professional Innovation Management Conference. Vienna, 21-24 June 2009.
23. Hughes B. Pharma pursues novel models for academic collaboration. Nat. Rev. Drug Discov. 7, 631-632 (2008).
24. Richards P. MIT, Novartis form partnership. MIT Tech. Talk 52, 1-6 (2007).
25. Alamo-Bethencourt V. GSK's Harvard cash injection. Nat. Biotech. 26, 956 (2008).